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www.haematologica.org/content/103/2/237No standard exists for the treatment of myelodysplastic syndromerelapsing after allogeneic stem cell transplantation. We performeda retrospective registry analysis of outcomes and risk factors in
698 patients, treated with different strategies. The median overall sur-
vival from relapse was 4.7 months (95% confidence interval: 4.1-5.3) and
the 2-year survival rate was 17.7% (95% confidence interval: 14.8-
21.2%). Shorter remission after transplantation (P<0.001), advanced dis-
ease (P=0.001), older age (P=0.007), unrelated donor (P=0.008) and acute
graft-versus-host disease before relapse (P<0.001) adversely influenced
survival. At 6 months from relapse, patients had received no cellular
treatment, (i.e. palliative chemotherapy or best supportive care, n=375),
donor lymphocyte infusion (n=213), or a second transplant (n=110).
Treatment groups were analyzed separately because of imbalanced char-
acteristics and difficulties in retrospectively evaluating the reason for
individual treatments. Of the patients who did not receive any cellular
therapy, 109 were alive at 6 months after relapse, achieving a median
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ABSTRACT
Introduction
Relapse of the underlying disease is a major drawback of
allogeneic hematopoietic stem cell transplantation (HSCT)
for myelodysplastic syndrome (MDS) and secondary acute
myeloid leukemia (sAML) evolved from MDS, in particular
as a consequence of the increasing numbers of HSCT with
reduced intensity conditioning.1,2 As in other diseases,
there is no defined standard approach to the management
of post-transplant relapse.3 Several studies addressing the
outcome of post-transplant relapse in different myeloid
diseases have included patients with MDS.4-6 However, a
specified analysis for MDS was usually not performed, or
included only limited numbers of patients. Hence, no large-
scale analysis of risk factors, different treatment strategies
and outcomes of MDS relapse after HSCT is available. The
Chronic Malignancies Working Party (CMWP) of the
European Society for Blood and Marrow Transplantation
(EBMT) performed a retrospective, registry-based analysis
on adults with hematological relapse after allogeneic
HSCT. Data are intended to serve as a baseline and com-
parison for future trials using innovative approaches. 
Methods
Inclusion criteria for patients from the CMWP registry
comprised: (i) first allogeneic HSCT for MDS or sAML,
using matched related, mismatched related or matched
unrelated donors; (ii) age at HSCT ≥18 years; (iii) first
hematological relapse after transplant (excluding decreas-
ing chimerism or cytogenetic/molecular relapse); and (iv)
reliable documentation about the management of post-
transplant relapse. Patients had agreed to reporting data to
national and international registries before transplantation.
The study was approved by the ethical committee of the
Medical Faculty, University of Essen. All procedures com-
plied with the ethical standards of the responsible commit-
tees (institutional and national) and the revised version of
the Helsinki Declaration of 1975.
Based on the first treatment received during the first 6
months after relapse, three treatment groups were defined:
(i) patients who did not receive any cellular therapy; (ii)
patients who received donor lymphocyte infusion (DLI);
and (iii) patients who underwent a second allogeneic HSCT
(HSCT2). The 6-month cutoff was chosen, since >95% of
HSCT2 and >98% of DLI reported in published studies
were performed within the first 6 months after relapse.
Hence, the cumulative use of these strategies, as well as the
outcome of patients treated without cellular therapy, could
be studied. Patients who both received DLI and underwent
a subsequent transplant proceeded to the DLI group, if
HSCT2 was given >90 days after DLI, because 90 days
were regarded as sufficient to evaluate the effect of DLI.
Patients who received a second transplant <90 days after
DLI entered the HSCT2 cohort, since HSCT was consid-
ered as the decisive intervention for the long-term outcome.
Although being somewhat arbitrary, this classification
enabled patients receiving both DLI and HSCT2 to be
included in the analysis without uncontrolled bias.
Conditioning,7 graft-versus-host disease (GvHD)8 and remis-
sion before HSCT9 were defined as described previously. As
suggested5, the transfusion of peripheral blood stem cells or
bone marrow was defined as DLI, if no prior conditioning
and no prophylactic immunosuppression was given,
whereas HSCT2 was defined as infusion of donor periph-
eral blood stem cells or bone marrow following a condition-
ing regimen and with prophylactic immunosuppression
(refer to the Online Supplement for details). 
Statistics
Overall survival from relapse was the primary end-
point.10 Variables considered included characteristics of
patients and their disease, donors, transplant procedure,
and relapse (see the Online Supplement for details). Variables
were compared among treatment groups, using the chi-
square test for categorical variables and the Kruskal-Wallis
test for continuous ones. In patients receiving DLI or
HSCT2, cumulative incidence of relapse and non-relapse
mortality were analyzed by competing risks models, with
the starting time being the moment of DLI/HSCT2. In
addition to the factors mentioned above, the characteris-
tics of the DLI/HSCT2 were considered for risk analysis.
Outcomes of subgroups were compared using a log-rank
test. Cox proportional hazards regression models were
used for multivariable analyses of factors for time-to-event
endpoints. Variables were included if considered relevant
based on the univariate analysis (P-value <0.2), or known
to be so from the literature. Patients with missing predictor
data were included in the analysis by assigning them to
separate categories of the pertaining variables. Hazard
ratios (HR) and 95% confidence intervals (95% CI) are
reported. R Version 3.1.0, packages ‘survival’, ‘cmprsk’ and
‘mstate’11 and SPSS versions 18 and 23 (SPSS Inc. Chicago,
IL, USA) were used.
Results 
Patients’ characteristics and overall outcome 
A total of 698 patients fulfilled the inclusion criteria
(Table 1). The median interval between HSCT and hema-
C. Schmid et al.
238 haematologica | 2018; 103(2)
overall survival from this landmark of 8.9 months (95% confidence interval: 5.1-12.6). Their 2-year sur-
vival rate was 29.7%. Recipients of donor lymphocytes achieved a median survival from first infusion
of 6.0 months (95% confidence interval: 3.7-8.3) with a 2-year survival rate of 27.6%. Longer remission
after first transplantation (P<0.001) and younger age (P=0.009) predicted better outcome. Among recip-
ients of a second transplant, the median survival from second transplantation was 4.2 months (95% con-
fidence interval: 2.5-5.9), and their 2-year survival rate was 17.0%. Longer remission after first transplan-
tation (P<0.001), complete remission at second transplant (P=0.008), no prior chronic graft-versus-host
disease (P<0.001) and change to a new donor (P=0.04) predicted better outcome. The data enabled iden-
tification of patients benefiting from donor lymphocyte infusion and second transplantation, and may
serve as a baseline for prospective trials.   
tological relapse was 6.3 months (range, 1-160.8). The
median follow-up from relapse among survivors was 9.4
months (range, 0.7-119.8). The median overall survival
from relapse of the entire cohort was 4.7 months (95% CI:
4.1-5.3 months). The overall survival rate was 27.6%
(95% CI: 24.2-31.3%) at 1 year, 17.7% (95% CI: 14.8-
21.2%) at 2 years and 11.4% (95% CI: 8.8-14.7%) at 4
years (Figure 1). Progression or another relapse of
MDS relapse after allogeneic transplantation
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Table 1. Baseline characteristics of 698 patients relapsing after allogeneic stem cell transplantation for myelodysplastic syndrome or secondary acute
myeloid leukemia.
                                                                    Entire                           Patients receiving                                 Patients                        Patients                      P
                                                                   cohort                           no cellular therapy                                given DLI                        given a
                                                                                                                                                                        ± prior                     second HSCT
                                                                                                   Total            Alive without cell.              chemotherapy                      ± prior
                                                                                                                    therapy at 6 months               as primary                   chemotherapy
                                                                                                                         from relapse*                   intervention          as primary intervention         
Number of patients                                                    698                           375                              109                                          213                                         110
                                                                                     (100%)                     (54%)                        (16%)                                     (31%)                                    (16%)                             
Year of HSCT,                                                              2003                         2003                                                                            2002                                        2002                          0.005
(range)                                                                  (1994-2008)           (1994-2008)                                                              (1994-2008)                          (1994-2008)
Patients’ age at relapse        Median                      52.2                          53.3                             51.4                                         52.3                                         48.7                            0.04
(years)                                     (range)               (18.4-74.9)             (18.4-73.3)                (21.3-72.3)                            (18.7-74.9)                            (20.7-68.3)
Patients’ sex (n)                    Female                328 (47%)              164 (44%)                  44 (40%)                               116 (55%)                              48 (44%)                       0.03
                                                       Male                   370 (53%)              211 (56%)                  65 (60%)                                97 (46%)                               62 (56%)
Time from diagnosis             Median                       6.5                            7.0                               7.3                                           6.2                                           5.5                            0.001
to HSCT (months)                 (range)               (0.4-291.6)             (0.4-291.6)                (1.0-291.6)                            (0.8-143.2)                            (0.8-104.7)
Diagnosis at HSCT (n)         RA/RARS                 47 (8%)                   24 (8%)                    14 (17%)                                19 (11%)                                 4 (4%)                         0.12
                                                      RAEB                  107 (19%)               48 (16%)                   15 (18%)                                39 (22%)                               20 (22%)                           
                                                    sAML**                418 (73%)              231 (76%)                  53 (65%)                               121 (68%)                              66 (73%)                           
                                                    Missing                      126                            72                                27                                            34                                            20                                 
Stage at HSCT                       Untreated             144 (21%)               71 (19%)                   29 (27%)                                51 (24%)                               22 (20%)                      0.538
(n, %)                                            CR                    304 (44%)              171 (46%)                  42 (39%)                                84 (39%)                               49 (45%)                           
                                                  Relapse/                77 (11%)                48 (13%)                   15 (14%)                                 18 (9%)                                11 (10%)                           
                                               progression
                                          Primary refractory      173 (25%)               85 (23%)                     23 (21)                                 60 (28%)                               28 (26%)                           
Donor (n, %)                    Matched family         398 (57%)              190 (51%)                  59 (54%)                               135 (63%)                              73 (66%)                       0.14
                                          Mismatched family     300 (43%)              185 (49%)                 50  (46%)                               78 (37%)                              373 (34%)                          
                                               or unrelated                                                                                                                                                                                                                             
Sex match donor/           Female in male         117 (17%)                72(20%)                    22(21%)                                27 (13%)                               18 (16%)                       0.19
recipient (n, %)                       Other                   571 (83)                296 (80%)                  84 (79%)                               183 (87%)                              92 (84%)                           
                                                    Missing                       10                              7                                  3                                              3                                              -                                  
Conditioning                           Standard               413 (59%)                216 (58)                    63 (58%)                               128 (60%)                              69 (63%)                       0.76
(n, %)                                        Reduced               285 (41%)              159 (42%)                  46 (42%)                                85 (40%)                               41 (37%)                           
T-cell depletion                           No                    383 (56%)              213 (58%)                  58 (54%)                               106 (51%)                              64 (60%)                       0.70
before HSCT (n, %)               In vivo                 199 (29%)              106 (29%)                  33 (31%)                                66 (31%)                               27 (25%)                           
                                                    Ex vivo                   53 (8%)                   27 (7%)                     10 (9%)                                  19 (9%)                                  7 (7%)                             
                                           In vivo+ ex vivo          48 (7%)                   20 (6%)                      6 (6%)                                   19 (9%)                                  9 (8%)                             
                                                    Missing                       15                              9                                  2                                              3                                              3                                  
Stem cell source                        BM                    176 (26%)               92 (25%)                   36 (34%)                                57 (27%)                               27 (25%)                       0.29
at HSCT (n, %)                          PBSC                  515 (75%)              276 (75%)                  71 (66%)                               156 (73%)                              83 (76%)                           
                                                    Missing                        7                               7                                  2                                               -                                               -                                  
Acute GvHD grade 2-4               No                    538 (79%)              266 (73%)                  82 (77%)                               182 (88%)                              90 (85%)                       0.05
after first HSCT                          Yes                    141 (21%)              100 (27%)                  24 (23%)                                25 (12%)                               16 (15%)                           
                                                    Missing                       19                              9                                  3                                              6                                              4                                  
Chronic GvHD after first          No                    394 (73%)              204 (71%)                  60 (64%)                              143 (77%)                             47 (73%)                       0.06
HSCT (n, %)                                Yes                    143 (27%)               84 (29%)                   34 (36%)                                42 (23%)                               17 (27%)                           
                                                    Missing                      161                            87                                15                                            28                                            46
Remission duration               Median                       6.3                            5.8                               9.6                                           6.6                                           7.1                            0.009
after HSCT (months)            (range)               (1.0-160.8)             (1.0-160.8)               (1.3-160.8)                            (1.0-148.3)                            (1.7-134.9)                         
(n, %)         <6 months            329 (47%)              193 (52%)                  28 (26%)                                92 (43%)                               44 (40%)                           
                                               6-12 months            202 (29%)              105 (28%)                  40 (37%)                                63 (30%)                               34 (31%)                           
                                                >12 months            167 (24%)               77 (21%)                   41 (38%)                                58 (27%)                               32 (29%)                           
HSCT: hematopoietic stem cell transplantation; RA: refractory anemia; RARS: refractory anemia with ring sideroblasts; RAEB: refractory anemia with excess of blasts; sAML: secondary acute
myeloid leukemia. CR: complete remission. GvHD: graft-versus-host disease. *The ‘no cellular therapy’ group contained patients who never received cellular therapy due to early death, as
well as patients whose follow-up was not long enough to ascertain if they had received cellular therapy or not. To avoid bias, only those patients were included into the comparison among
treatment cohorts, of whom it was certain that they survived for ≥6 months from relapse and had not received any cellular treatment.** Patients initially classified as having RAEB-T have
been classified as having sAML, using the current WHO definition of AML (≥ 20% blasts in the bone marrow).
MDS/sAML was the leading cause of death (82.1% of
deaths). The remaining deaths were from causes related to
HSCT or cellular therapy (14.9%), secondary malignan-
cies (0.7%) or other causes (2.2%). A risk factor analysis
for outcome after relapse was performed. Results from
univariate analysis are shown in Online supplementary Table
S1. Table 2 shows the results of the multivariate analysis
for overall survival, based on variables available at the
time of the relapse. In the multivariate model, a longer
remission after HSCT (>12 months, HR 0.4, and 6-12
months HR 0.6, P<0.001), an earlier stage of MDS at time
of HSCT (refractory anemia with excess blasts and sAML
versus refractory anemia/refractory anemia with ring sider-
oblasts; HR 1.6 and 2.0, P=0.001), younger age at relapse
(HR 1.01 per year, P=0.005), donor type (unrelated donor
versus HLA-identical sibling, HR 1.3, P=0.005) and no his-
tory of acute GvHD before relapse (HR 0.6, P<0.001) were
associated with better overall survival from relapse.
Outcome according to the treatment applied
In the first 6 months from relapse after HSCT, 213
patients were reported to have received DLI, and 110 to
have undergone HSCT2. The other 375 patients had not
received any cellular treatment: 109 of these were still
alive and in follow-up 6 months after their relapse. Since
patients who died early after relapse or whose follow-up
was short did not have enough time for the transition to
one of the two other groups, the comparison among treat-
ment groups was only based on patients still in the group
not having received any cellular therapy at 6 months after
relapse, to avoid bias due to the high early mortality that
by definition had to take place in this group. 
To assess the time-dependent probability of receiving a
cellular intervention in the first 6 months after relapse, or
remaining alive cellular-treatment free, a competing risks
analysis, accounting also for loss from follow-up, was per-
formed. All patients started in the cellular-treatment free
group, and could subsequently proceed to one of the other
groups. DLI, HSCT2 and death without any cellular ther-
apy (whichever occurred first) were considered as com-
peting events (Figure 2).    
Patients’ characteristics such as age or duration of remis-
sion after HSCT were significantly different among the
three treatment groups (Table 1). Furthermore, treatment
Figure 2. Cumulative incidence of treatments applied during the first 6
months. The plots are stacked: the distance between two lines (and, for the
uppermost curve, the distance from the curve to 100%) indicates the cumula-
tive incidence as a function of time. At 6 months after relapse, the cumulative
probability of having received a DLI (bottom group) was 31% (95% CI: 28-35%)
and that of having undergone HCT2 (second group from the bottom) was 17%
(95% CI: 14-19%). Thirty-five percent had died without having received DLI or
HSCT2 (second group from top), whereas 18% (95% CI: 15-21%) of patients
were still in the cellular treatment-free group (uppermost group).
Table 2. Multivariate analysis of risk factors for overall survival from relapse
in 698 patients.
                                             HR 95% CI for HR                   P
                                         for death lower            upper                
Donor type                                                                                                                  0.005
HLA-identical sibling               1
Unrelated/mismatched         1.3                           1.1                       1.5
relative                                         
MDS subtype at HSCT*                                                                                     0.001
RA/RARS                                      1                                                                                     
RAEB                                           1.6                           1.0                      2.48                 0.035
sAML                                           2.0                          1.54                      2.9                 <0.001
Acute GvHD before relapse*                                                                          <0.001
No                                                 1
Yes                                              1.6                           1.3                      1.92
Age at relapse                                                                                  0.005
(as continuous variable,        1.010                       1.003                   1.016
per year)**                                                                   
Remission after HSCT
< 6 months                                 1                                                                               <0.001
6-12- months                             0.6                           0.5                       0.7                 <0.001
> 12 months                             0.4                           0.3                       0.5                 <0.001
HR: hazard ratio; CI: confidence interval; MDS: myelodysplastic syndrome; HSCT: hematopoiet-
ic stem cell transplantation; RA: refractory anemia; RARS: refractory anemia with ring siderob-
lasts; RAEB: refractory anemia with excess of blasts; sAML: secondary acute myeloid leukemia;
GvHD: graft-versus-host disease.*Patients with missing data were retained in the analysis by
assigning them to a separate category (hazard ratios not shown). **Impact of an age differ-
ence at relapse of (e.g.) 10 years translates into a hazard ratio of 1.10.
Figure 1. Overall survival from relapse in 698 patients. Overall survival (OS)
from relapse of the entire cohort (gray area denotes 95% confidence interval,
CI, over time) The median overall survival was 4.7 months (95% CI: 4.1-5.3
months).
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decisions in the reporting centers had not been based on a
general strategy, but had been made individually for each
patient. Therefore, the reason for assigning a given patient
to one of the treatment modalities could not be evaluated
retrospectively at a reliable level. The three treatment
cohorts were, therefore, evaluated separately, and no
comparison of outcome was performed. 
Patients not receiving any cellular treatment (n=375)
The treatment approaches applied among patients not
receiving any cellular intervention ranged from palliation
only to mild and intensive chemotherapy. However,
detailed information on choice and dosage of the drugs
used was not available. At last follow-up, 266 patients
had died without having received DLI or HSCT2: report-
ed causes of death were MDS/sAML in 92%, and HSCT-
related events in 7%. For the 109 patients alive at 6
months after relapse, the median overall survival from
this landmark was 8.9 months (95% CI: 5.1-12.6). The 2-
year overall survival rate was 29.7% (95% CI: 20.1-
39.3%). Since the vast majority of DLI and HSCT2 had
been given within the first 3 months after relapse, anoth-
er landmark analysis was performed, including 221
patients who had been alive without any cellular therapy
by day 90. The median overall survival from this land-
mark was 6.1 months and the 2-year overall survival rate
was 23.8%
Patients receiving a second stem cell transplant (n=110)
The characteristics of second transplants are shown in
Table 3. Only 9% of patients underwent HSCT2 while in
complete remission, whereas 90% had active disease. The
median interval from relapse to HSCT2 was 1.7 months
(range, 0.2-6.0). Seventy-six percent received the HSCT2
from the original donor, whereas a new donor was used in
24%. Following HSCT2, 45 patients (46% of informative
cases) achieved complete remission; 16 of them developed
another relapse at a median of 4.6 months (range, 1.8-37.8)
after HSCT2. Acute GvHD grade II-IV and chronic GvHD
developed in 24.8% and 34.6%, respectively, of informa-
tive patients.
The median follow-up was 11.0 months among sur-
vivors. The median overall survival from HSCT2 was 4.2
months (95% CI: 2.5-5.9), while the overall survival rates
at 1, 2 and 4 years were 22.3% (95% CI: 13.9-30.7%),
17.0% (95% CI: 10.7-27.1%) and 12.4% (95% CI: 5.1-
19.7%), respectively. (Figure 3A). The cumulative inci-
dence of relapse/progression was 35% (95% CI: 26-45%)
at both 1 and 2 years, whereas the cumulative incidence of
non-relapse mortality was 45% (95% CI: 35-55%) at 1
year and 49.3% (95% CI: 39-59%) at 2 years after HSCT2. 
A risk factor analysis for overall survival from HSCT2
was performed, including variables known at the time of
HSCT2. Results of the univariate analysis are provided in
Online Supplementary Table S2. Among other factors, a his-
tory of DLI given prior to HSCT2 did not influence the
overall outcome. In a multivariate Cox model (Table 4A) a
sibling donor for HSCT1, no history of chronic GvHD
after HSCT1, a longer remission after HSCT1, and HSCT2
in complete remission were strongly associated with bet-
ter overall survival after HSCT2. With respect to disease
stage, the median overall survival after HSCT2 in com-
plete remission was 37.8 months, as compared to only 2.9
months after HSCT2 in active disease (univariate compar-
ison). There was also an advantage for those patients
undergoing HSCT2 from a different donor (P=0.044, HR
0.562, 95% CI: 0.321-0.984). The role of remission dura-
tion (P=0.002) and stage (P=0.022; univariate Kaplan-
Meier estimates) is illustrated in Figure 3B,C.
Patients receiving donor lymphocyte infusion (n=213)
The median interval from relapse to first DLI was 21
days (range, 0-170). The initial cell dose was 1x107 CD3+
cells/kg (range, 0.3-187). Of the informative patients,
Table 3. Characteristics and early outcome of second transplant in 110
patients.
Characteristics                                                                                              N
                                                                                                             (range or %)
Interval between HSCT1 and HSCT2 (months)                 Median                        9.4 
                                                                                                       (range)                 (2.3-135.8)
Interval between relapse and HSCT2 (months)               Median                        1.7 
                                                                                                       (range)                   (0.2-6.0)
DLI given for relapse <90 days before HSCT2                   N. (%)                    12 (11%)
                                                                                             Days between DLI 
                                                                                                    and HSCT2
                                                                                               (median, range)         49.5 (0-89)
Stage at HSCT2, n (%)                                                                 CR                        9 (10%)
                                                                                                Active disease            85 (90%)
                                                                                                       Missing                         16
Donor for HSCT1                                                           HLA identical family       73 (66%)
                                                                                         Unrelated/mismatched    37 (34%)
                                                                                                         family
Donor for HSCT2                                                           HLA identical family       70 (64%)
                                                                                        Unrelated/mismatched    39 (36%)
                                                                                                       family
                                                                                                       Missing                          1
Donor change* from HSCT1 to HSCT2, n (%)    Same donor for HSCT2    83 (76%)
                                                                                          New donor for HSCT2     26 (24%)
                                                                                                       Missing                          1
Conditioning for HSCT2, n (%)                                            Standard                 46 (43%)
                                                                                                      Reduced                 61 (57%)
                                                                                                       Missing                          3
TBI for conditioning before HSCT2                                           Yes                      24 (23%)
                                                                                                           No                       80 (77%)
                                                                                                       Missing                          6
Source of stem cells for HSCT2                                                BM                         8 (7%)
                                                                                                           PB9                       8 (91%)
                                                                                                       BM+PB                     1 (1%)
                                                                                                    Cord blood                 1 (1%)
                                                                                                       Missing                          2
Outcome                                                                                                                           
Engraftment, n (%)                                                                      Yes                      80 (79%)
                                                                                             Yes, but secondary          2 (2%)
                                                                                                   graft failure                       
                                                                                                           No                       19 (19%)
                                                                                                       Missing                          9
Time to neutrophil engraftment, days                         Median (range)          13 (0-102)
Time to platelet engraftment, days                              Median (range)          20 (7-263)
Response after HSCT2, n (%)                                         Early death**             16 (16%)
                                                                                                          CR                       45 (46%)
                                                                                                       No CR                    37 (38%)
                                                                                                     Unknown                       12
HSCT: hematopoietic stem cell transplantation; DLI: donor lymphocyte infusion; BM: bone mar-
row; PB: peripheral blood; CR: complete remission. *Either from a matched family to an unre-
lated donor or from one unrelated donor to another. ** Early death was defined as death <1
month from HSCT2 and without re-occurrence of myelodysplastic syndrome or secondary
acute myeloid leukemia.
MDS relapse after allogeneic transplantation
haematologica | 2018; 103(2) 241
68.6%, 17.1% and 14.3% received one, two and three
infusions, respectively. The median follow-up of the 50
patients alive at last contact was 18.2 months (range, 0.03-
105.1). Following DLI, acute GvHD grade 2-4 was
observed in 14 patients (26.4% of informative cases).
Limited and extensive chronic GvHD were reported in 15
and 13 patients, respectively. While response rate to DLI
was not reported for a considerable number of patients, the
median overall survival from first DLI was 6.0±1.2 months
(95% CI: 3.7-8.3); overall survival rates at 1, 2 and 4 years
were 36.1±3.5%, 27.6±3.3% and 17.0±3.2%, respectively
(Figure 4A).  Reported causes of death were MDS/sAML
(81.7%), HSCT related causes (12.4%), secondary malig-
nancies (2.6%), and other causes (3.3%). Results of the uni-
variate analysis of risk factors for overall survival from first
DLI are provided in Online Supplementary Table S3. A mul-
tivariate Cox model revealed a longer remission after
HSCT (most significant), younger age, and male sex as sig-
nificant protective parameters (Table 4B). Some patients
achieved long-term survival after receiving a second trans-
plant following the failure of DLI. Figure 4B illustrates the
role of remission duration (P<0.001, univariate Kaplan-
Table 4A. Multivariate analysis of risk factors for overall survival from second
transplant in 110 patients.
                                                             HR 95% CI for HR            P
                                                        for death           lower         upper             
Donor type at HSCT1                                                                                             0.018
HLA-identical sibling                                   1                                                                      
unrelated/mismatched                             1.8                      1.1                 2.9                   
Cell source at HSCT1                                                                                               0.185
Bone marrow                                                1                                                                      
Peripheral blood                                        1.5                      0.8                 2.5                   
Chronic GvHD before relapse*                                                                          <.001
No                                                                    1                                                                      
Yes                                                                 4.4                      2.2                 8.9                   
Remission after HSCT                                                                                            <0.001
< 6 months                                                    1                                                                      
< 6 months vs. 6-12 months                   0.5                      0.3                 0.8              0.003
< 6 months vs. > 12 months                   0.3                      0.2                 0.6             <0.001
Stage at second HSCT*                                                                                               
Complete remission                                   1                                                                      
Active disease                                             3.8                     1.49               10.4             0.008
Donor change for HSCT2 *                                                                                   0.044
Same donor for HSCT2                              1                                                                      
Donor change for HSCT2                         0.6                      0.3                 1.0                   
HR: hazard ratio; CI: confidence interval; HSCT: hematopoietic stem cell transplantation; GvHD:
graft-versus-host disease.
Table 4B. Multivariate analysis of risk factors for overall survival after first ther-
apeutic donor lymphocyte infusion in 213 patients.
                                                             HR 95% CI for HR            P
                                                        for death           lower         upper             
Patients’ sex                                                                                                                 0.014
Male                                                                1
Female                                                          1.5                      1.1                 2.2
Stage at HSCT1                                                                                                           0.521
Untreated                                                      1                                                                      
Complete remission                                 1.2                      0.9                 1.9              0.313
Relapsed/progressive disease                1.3                      0.8                 1.9              0.303
Donor type at HSCT1                                                                                                0.080
HLA-identical sibling                                   1                                                                      
Unrelated/mismatched                          1.4                      1.0                 1.9                   
Chronic GvHD before relapse*                                                                                
No                                                                    1                                                                      
Yes                                                                 1.0                      0.6                 1.6              0.904
Age at relapse                                                                                                              0.009
(as continuous variable, per year)        1.017                  1.004             1.030                 
Remission after HSCT                                                                                            <0.001
< 6 months                                                    1                                                                      
6-12 months                                                0.7                      0.5                0.1.0             0.048
> 12 months                                               0.4                      0.2                 0.6              <.001
HR: hazard ratio; CI: confidence interval; HSCT: hematopoietic stem cell transplantation; GvHD:
graft-versus-host disease.*Patients with missing data were retained in the analysis by assigning
them to separate categories (hazard ratios not shown). 
Figure 3. Overall survival after second transplant. (A) Within the entire cohort of 110 patients (gray area denotes 95% confidence interval, CI, over time; 2-year over-
all survival: 17.0, 95% CI: 10.7-27.1%). (B) As of remission duration after first transplantation, (>12 months, solid line, 2-year overall survival 36.6%, 95% CI: 21.9-
61.0 ; 6-12 months, dashed line, 2-year overall survival 14.9%, 95% CI: 6.3-35.7; <6 months, dotted line, 2-year overall survival 5.9%, 95% CI: 15.7-22.3) P=0.002.
(C) As of remission status at time of second transplant (complete remission, solid line, 2-year overall survival 59.3%, 95% CI: 32.2-100%; active disease, dotted line,
2-year OS 11.1%, 95% CI: 5.5-22.4%) P=0.022.
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Meier estimate). If post-transplant remission exceeded 1
year, the median overall survival was 25.1 months (95%
CI: 8.4-41.8) and the 2-year overall survival rate was 51.3%
(95% CI: 39.1-67.2%).  
Discussion
In the largest group of patients relapsing after allogeneic
HSCT for MDS and sAML analyzed so far, less advanced
stage of MDS at transplant (refractory anemia/refractory
anemia with ring sideroblasts and refractory anemia with
excess blasts versus sAML), no history of acute GvHD after
HSCT, and a longer remission after HSCT were associated
with better overall survival after relapse. At 2 and 4 years
from relapse, 6% and 4% of patients, respectively, were
alive without having received a cellular treatment. During
the first 6 months after relapse, 31% of patients were
selected to receive DLI and 17% of patients received a sec-
ond HSCT. The 2-year overall survival rates from the
intervention in these selected subgroups were 28% for
DLI recipients, and 17% for patients receiving HSCT2.
While remission duration after HSCT1 was the most rele-
vant prognostic parameter both after DLI and after
HSCT2, no history of chronic GvHD after HSCT1, an
HLA-identical family donor for HSCT1, and controlled
disease at the time of HSCT2 were additional relevant fac-
tors for survival after a second transplant. Switching to an
alternative donor for HSCT2 was associated with a better
outcome. 
Despite the large number of patients included in this
analysis, the nature of a retrospective registry study
implies several limitations. Most importantly, cytogenet-
ic data were rather incomplete, thereby precluding calcu-
lation of the revised International Prognostic Scoring
System score and the analysis of outcome and efficacy of
different treatments in biologically defined risk groups.
On the other hand, cytogenetics has not been found to
play a major role in outcomes following post-transplant
relapse either in AML12 or MDS (with the exception of
very poor risk cytogenetic characteristics).13 Second, the
analysis is based on patients transplanted in the past, for
whom sufficient data of reasonable quality to perform
such a detailed analysis were available. To study a possi-
ble change in outcome of post-transplant MDS relapse
over time, we analyzed overall survival after relapse in a
more recent cohort of MDS patients, also derived from
the EBMT registry (transplantation years 2009-2012).
The outcomes of this cohort were almost identical to
those of our current study [median overall survival 5.0
months, 2-year overall survival rate 19% (95% CI 16-
21%), data not shown in detail]. Similarly, the 2-year
overall survival rate following post-HSCT relapse was
16% in a more recent smaller study,13 which compares
very well with our observation. We, therefore, believe
that our data are still valid for current patients, also illus-
trating the limited progress made in recent years in the
treatment of MDS relapsing after allogeneic HSCT, and
the urgent need for new concepts. As discussed below,
the broader use of hypomethylating agents might be a
way to improve outcomes in the future. However, so far
this has not been demonstrated in the various registry
analyses. 
The lack of precise data on disease status at the time of
relapse prevented distinguishing between relapse as MDS
versus sAML. This is another drawback of the analysis,
since bone marrow infiltration by leukemic blasts at the
time of relapse was a relevant factor for overall survival in
a recent analysis on patients relapsing after reduced inten-
sity conditioning HSCT for de novo AML.14 The percentage
of bone marrow blasts at relapse might also have influ-
enced the treatment approach after relapse. The reason
why no cellular therapy, DLI or a second transplant was
preferred in a given patient could not be determined retro-
spectively. Given the differences in patients’ characteris-
tics among the three treatment groups, and because the
group not given cellular therapy was a heterogeneous
mixture of patients who died early, patients with a short
follow-up and patients alive and truly untreated with DLI
or HSCT2, we decided to limit the overall analysis of risk
factors to variables that were known at the time of
relapse, and performed separate studies for the DLI and
HSCT2 subgroups. Hence, general conclusions for select-
ing treatment strategies cannot be drawn on the basis of
this analysis.
As shown in many studies on relapse after allogeneic
HSCT,5;12;14-17 remission duration after HSCT was the most
important variable for outcome, irrespective of the applied
treatment strategy. Patients with a history of acute GvHD
after HSCT1 had an inferior outcome, a finding that has
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Figure 4. Overall survival after first thera-
peutic donor lymphocyte infusion. (A)
Within the entire cohort of 213 patients, 2-
year overall survival was 27.6%, 95% confi-
dence interval (CI): 21.1-34.1.0%. Grey
area denotes 95% CI, over time (B) As of
remission duration after HSCT1 (>12
months, solid line, 2-year overall survival
51.3%, 95% CI: 39.1-67.2%; 6-12 months,
dashed line, 2-year overall survival 30.8%,
95% CI: 20.2-46.8%; <6 months, dotted
line, 2-year overall survival 11.0%, 95% CI:
5.9-20.4%) P<0.001.
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similarly been reported after relapse from reducing inten-
sity conditioning HSCT for de novo AML14 and acute lym-
phocytic leukemia,17 and in a recent French study on
relapsed MDS.13 However, in our cohort, 23% of patients
who did not receive any cellular therapy for post-trans-
plant relapse had developed acute GvHD of grade II-IV
after HSCT1, in contrast to only 12% and 15% among
patients who received DLI or HSCT2, respectively
(P=0.05). Hence, a history of acute GvHD might not nec-
essarily be a risk factor as such, but may have contributed
to the decision not to consider DLI or HSCT2 in a given
patient, or may have been associated with an inferior per-
formance at the time of relapse, leading to less intensive
treatment. Similarly, the history of a related donor trans-
plant may have influenced the application of a donor cell
based strategy (i.e. DLI or second transplant), and younger
age may have been a criterion for offering HSCT2. 
Precise information on 110 patients undergoing HSCT2
allowed for a detailed analysis of this strategy. The role of
disease control before HSCT2 was a striking observation.
Although only 10% of patients received HSCT2 in com-
plete remission, stage at HSCT2 was a significant factor for
outcome in multivariate analysis, and median overall sur-
vival after HSCT2 in complete remission was 37 months, as
compared to only 2 months after HSCT2 in active disease
(Figure 3B; the large confidence intervals underscoring the
need for confirmatory studies). Nevertheless, selection of
patients during and after chemotherapy precludes firm rec-
ommendations. Similar results have been reported recently
in a large German study on HSCT2 for acute leukemia in
the related and unrelated donor setting,18 and in an EBMT
analysis on DLI for post-transplant relapse of de novoAML.10
Unfortunately, data on remission status at time of DLI in
our study were not sufficient to reproduce these findings
among DLI recipients.
Switching to a different donor for HSCT2 showed a lim-
ited, although statistically significant, advantage for over-
all survival (HR: 0.562, 95% CI: 0.321-0.984 in the multi-
variate model). This observation is in line with those of
several studies addressing this issue in acute leukemia,16,18
indicating that a change of donor is definitely not disad-
vantageous, and seems to offer a slight improvement in
certain subgroups. Hence, our data add to the growing evi-
dence, that changing to another donor is a justifiable
option for HSCT2. Donor switching might be more prom-
ising among patients receiving HSCT2 for controlled dis-
ease, whereas in patients with a short post-transplant
remission or in uncontrolled disease, the aggressiveness of
the underlying malignancy will most likely overwhelm a
putatively improved graft-versus-leukemia reaction of a
new donor. Change to a haploidentical family donor
might be another option, given the more rapid availability
and the greater HLA disparity.19
Finally, patients without a history of chronic GvHD after
HSCT1 had a better outcome after HSCT2, suggesting that
in these patients, the graft-versus-leukemia effect might not
yet have been exploited before post-transplant relapse.
In summary, we provide data on a large cohort of con-
secutively reported patients with relapsed MDS and
sAML after allogeneic HSCT, discussing the difficulties
and limitations of such a retrospective registry analysis. As
in a recent French study, which showed comparable over-
all results in a smaller cohort,13 relapse or progression was
by far the leading cause of death, underscoring the need
for innovative strategies. Without a graft-versus-leukemia-
based intervention (i.e., DLI or HSCT2), only a few
patients survive more than 2 years after relapse. In con-
trast, DLI or second HSCT showed certain, albeit still lim-
ited, efficacy in selected patients, such as patients in
whom the interval between HSCT and relapse was long,
or patients who responded to chemotherapy. In the EBMT
analysis on AML relapse after reduced intensity condition-
ing HSCT, a donor cell-based intervention was shown to
be mandatory for long-term remission even in these posi-
tively selected patients.14 Similar findings emerged from
the French study on post-HSCT MDS relapse mentioned
above. In contrast, patients in whom the interval between
HSCT and relapse is short or patients with overt AML and
high blast counts have a grim prognosis and are not likely
to benefit from the traditional interventions after relapse.
Our results may serve as a baseline to which new
approaches can be compared, as they give a large-scale-
based estimate of the results to be expected after use of
each approach in the treatment of MDS relapse after allo-
geneic HSCT. At present, hypomethylating agents (azacy-
tidine, decitabine) alone or in combination with DLI seem
to be among the most promising compounds for the treat-
ment of post-transplant relapse in myeloid malignan-
cies,20,21 because of both their direct antileukemic efficacy
and their immunomodulatory capacity.22-26 Checkpoint
inhibitors might be an option for the future.27 Strategies
for prophylactic28-30 or preemptive31-33 treatment in high-
risk patients are promising alternatives to avoid overt
hematologic relapse, while targeting molecular aberra-
tions such as Flt3-internal tandem duplication, or inhibi-
tion of histone deacetylase34 and prophylactic DLI are
promising approaches to post-transplant maintenance. 
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